Article
Apr 5, 2026
The challenges of nephrology practice and CKD progression
Understand why CKD progression remains a clinical challenge and how renal clinical research can expand management possibilities in nephrology.
The nephrology routine is marked by a tension that few specialists can precisely name: the space between what the current therapeutic arsenal offers and what patients with CKD actually need.
This is not an exclusively technical gap, but a clinical reality that imposes itself every day, regardless of the level of experience or the service in which the nephrologist works.
This distance manifests in different ways: in late referral, in the patient who progresses despite optimized treatment, in the multiplicity of comorbidities that make each decision more complex than the protocol suggests.
The progression of Chronic Kidney Disease rarely follows a linear and predictable path, and clinical management increasingly requires a longitudinal view that goes beyond isolated laboratory parameters.
This article does not intend to review what the nephrologist already masters. It starts from a recognition of the complexity inherent to kidney care to explore what science has shifted in the understanding of the disease, and where renal clinical research enters as an active part of this equation. Enjoy the reading.
The reality of the nephrologist’s routine in patients with CKD
The truth is that nephrologists working in specialized outpatient care know that a significant portion of their patients arrive with therapeutic windows already narrowed.
The nephrology routine is, to a large extent, a routine of damage control and management of clinical expectations — which is not a shortcoming, but an inevitable context of advanced kidney care.
CKD progression does not present uniformly among patients. Two individuals with the same disease stage, similar proteinuria, and comparable history may progress in completely different ways.
This heterogeneity is not only in genetic markers. It is in referral timing, comorbidities, and also in individual treatment responses.
Recognizing this variability is the starting point for understanding why the nephrology routine remains a clinically challenging field, even with scientific advances in recent years. Assertive, well-qualified management requires looking beyond the medical record.
Patients arrive late to the specialist
A recurring finding in the medical literature is that a significant share of patients with chronic kidney disease reaches the nephrologist already in advanced stages of the disease.
A study published in Kidney International indicates that late referral is associated with worse long-term outcomes, greater need for kidney replacement therapy, and increased cardiovascular mortality.
When the patient finally enters the specialized flow, the margin for intervention to modify the trajectory of Chronic Kidney Disease progression is already reduced.
Late referral is not just a care-flow problem. It is a clinical conditioning factor that shapes what is possible to do in practice and reinforces the importance of broadening the perspective beyond the specialized office.
Silent CKD progression, even with treatment
Renal progression in patients under specialized follow-up is a well-documented and clinically frustrating phenomenon.
Some patients continue progressing to more advanced stages even with optimized treatment, suggesting that the mechanisms involved go beyond currently available approaches.
An analysis published in the Journal of the American Society of Nephrology (JASN) showed that the eGFR decline rate can vary significantly among patients with apparently similar profiles, indicating that factors not yet fully understood modulate the speed of CKD progression.
This reality places the nephrologist in a permanent position of vigilance: monitor, adjust, interpret — and, often, acknowledge that current treatment was not enough to alter the course of the disease.
➔ Join the Medical Referral Program by Synvia and connect your patients to the latest renal clinical research initiatives.
Multiple comorbidities competing for therapeutic priority
In the nephrology routine, it is common to follow patients with chronic kidney disease who also have other clinical conditions capable of influencing CKD progression. Among the most frequent comorbidities are:
Diabetes mellitus: one of the leading causes of CKD worldwide. Metabolic changes associated with prolonged hyperglycemia may contribute to progressive glomerular damage and accelerate disease progression.
Arterial hypertension: hypertension is closely related to deterioration of renal function. Elevated blood pressure levels can increase hemodynamic overload in the glomeruli, favoring CKD progression.
Cardiovascular disease: patients with chronic kidney disease are at higher risk of cardiovascular events, such as heart failure and coronary artery disease.
Metabolic syndrome: characterized by the combination of abdominal obesity, insulin resistance, dyslipidemia, and hypertension, metabolic syndrome is associated with inflammatory and metabolic changes that may contribute to CKD progression.
Managing CKD in patients with multiple chronic conditions involves constant prioritization, negotiation of approaches with other specialties, and a systemic reading that considers the patient as a whole, not only isolated renal function.
The impact of this complexity on the nephrology routine is real and daily: it increases consultation time, requires more structured interprofessional communication, and makes longitudinal monitoring substantially more demanding.
CKD progression that does not always track symptoms
Because it is silent, the patient may advance from one stage to another without showing symptoms that justify, in their perception, the urgency of medical follow-up, contributing to Chronic Kidney Disease progression not identified in time.
Clinical decision-making in nephrology often needs to occur before worsening becomes clinically evident. This implies significant dependence on laboratory markers, trends in functional decline, and longitudinal data — and a certain vulnerability to short-term variations that may mask more concerning trends.
Acting before symptomatic worsening is, at the same time, the central premise of good kidney care and one of the greatest practical difficulties of the contemporary nephrology routine — and a concrete argument for denser follow-up structures.
The nephrologist’s central challenge: slowing CKD progression
Partial control vs. actual interruption of progression
The clinical objective of slowing CKD progression is, in theory, well established. In practice, however, the difference between partially controlling the speed of decline and effectively modifying the disease course is considerable — and it is in this difference that one of the greatest tensions of the contemporary nephrology routine lies.
Currently available approaches have shown varied and relevant benefits in specific subpopulations, but response heterogeneity is substantial.
Some patients show prolonged stability; another portion continues to progress regardless of instituted interventions — a pattern that renal clinical research has sought to understand in greater depth.
This reality reinforces the need to expand the available repertoire. This is exactly where renal clinical research takes on a structural, not peripheral, role in the advancement of nephrology.
Heterogeneity of patients with CKD
Heterogeneity is, perhaps, the word that best defines the CKD population. Differences in etiology, progression speed, cardiovascular risk profile, and response to interventions make direct application of population-level results to the individual patient difficult.
This variability has increasingly been incorporated into nephrology clinical research studies, which seek to identify subgroups with distinct risk profiles and differentiated response patterns.
Advancement in this direction requires data volume that can only be built with active and continuous participation from specialized research centers.
The nephrologist working at the interface between clinical practice and research contributes directly to refining this understanding — and, at the same time, offers their patient access to investigational protocols that may not be available in another care context.
The weight of cardiovascular risk in renal evolution
The relationship between kidney and cardiovascular system is bidirectional and clinically relevant. CKD progression increases cardiovascular risk, and cardiovascular events accelerate renal function decline — a cycle that multiplies the complexity of care and requires an integrated vision.
This kidney-heart interaction is one of the central axes in new approaches to chronic kidney disease, and its understanding has shifted the focus of renal management to a broader cardiorenal perspective — with direct implications for the design of clinical studies.
➔ Connect your clinical practice to research. Sign up for Synvia’s Medical Referral Program.
Why does Chronic Kidney Disease remain complex to manage?
The great truth is that the complexity of Chronic Kidney Disease management is not the result of lack of knowledge; it is simply the result of the disease’s complex, multifactorial nature.
A review published in the New England Journal of Medicine highlighted that CKD involves interconnected injury mechanisms that make single and linear therapeutic approaches difficult. Continue reading to understand more about the topic.
Cumulative damage and multiple pathophysiological mechanisms
Renal injury in CKD is, by definition, cumulative. Each injury episode — whether hemodynamic, inflammatory, or metabolic in origin — leaves a damage substrate that is not completely reversible.
CKD progression reflects, to a large extent, this sum of aggressions over time on functional tissue with limited regeneration capacity.
Multiple mechanisms act simultaneously: intraglomerular hemodynamic alterations, activation of inflammatory pathways, oxidative stress, and disruption of tubular energy metabolism.
None of these mechanisms operates in isolation, which partly explains why interventions directed at a single target have limited impact on modifying renal progression.
Growing understanding of this complexity has directed research toward approaches that act on multiple mechanisms simultaneously — a trend that marks the current state of science in nephrology and requires robust clinical data for validation.
Inflammation, fibrosis, and structural remodeling
The transition from acute damage to progressive chronic injury involves persistent inflammation and renal fibrosis — phenomena that represent the final histological substrate of CKD progression.
The structural remodeling accompanying these processes irreversibly compromises renal architecture, limiting functional recovery even when the original aggressive factor is controlled.
Studies in renal biopsy and experimental models have expanded understanding of the mediators of this process, identifying potential targets that still lack structured clinical translation.
This is an area in which clinical trials play an irreplaceable role: not only to confirm assertiveness, but to understand in which patients certain interventions make a true clinical difference.
Kidney-heart-metabolism integration
The cardiorenal-metabolic axis has emerged as one of the most transformative concepts in the contemporary understanding of chronic kidney disease.
Kidney, heart, and metabolism are not independent systems that occasionally interact — they co-evolve in a scenario of shared risk, especially in patients with diabetes and obesity.
This integration has direct implications for CKD management: decisions that affect the patient’s metabolic profile impact renal function, and vice versa.
Clinical reasoning isolated by specialty may be insufficient to capture this interdependence, which reinforces the logic of multiprofessional approaches and studies that evaluate composite outcomes.
Incorporating this perspective into new approaches to chronic kidney disease represents one of the most significant movements in the field in recent years, and has been the driver of some of the most relevant ongoing clinical trials.
➔ Connect your patients to science. Sign up for Synvia’s Medical Referral Program.
Where do clinical studies fit into the advancement of nephrology?
Despite recent advances, nephrology still has relevant therapeutic gaps. Clinical research in nephrology faces specific challenges: heterogeneous populations, long-term outcomes, recruitment difficulty, and underrepresentation of groups that are, paradoxically, the most affected.
Results obtained in controlled clinical trials do not always translate immediately into broad clinical practice — especially in patients with multiple comorbidities who are usually underrepresented in the inclusion criteria of pivotal studies.
Referral to clinical studies by attending nephrologists is one of the most qualified mechanisms to overcome this limitation.
Specialized centers with high patient volume contribute structurally to generating relevant evidence — and to ensuring that renal clinical research results truly reflect the complexity of the real population.
Synvia’s Medical Referral Program integrates clinical practice and research
Synvia developed the Medical Referral Program with the objective of creating a structured bridge between the attending nephrologist and ongoing clinical research initiatives.
The program was designed so that the referral process is clear, assertive, and compatible with the reality of the nephrology routine — without imposing additional administrative burden on the attending physician.
The communication flow between the research team and the attending physician is one of the pillars of the program. The nephrologist who refers a patient remains informed about the case’s evolution in the study context, maintaining continuity of care and integrity of the therapeutic relationship.
Eligibility criteria are presented transparently, allowing the physician to autonomously assess which patients may benefit from referral.
Participating in the Medical Referral Program is a concrete way to integrate renal clinical research into daily clinical practice, contributing to scientific advancement and offering patients access to investigational protocols that may expand their care possibilities.
Tap the button below now and learn more about Synvia’s Medical Referral Program.
_______________________________________________________________________________
REFERENCES
WAVAMUNNO, M. D.; HARRIS, D. C. H. The need for early nephrology referral. Kidney International, v. 67, suppl. 94, p. S128-S132, Apr. 2005. DOI: 10.1111/j.1523-1755.2005.09429.x. Available at: https://www.kidney-international.org/article/S0085-2538(15)50789-8/fulltext
GRAMS, M. E. et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. Journal of the American Society of Nephrology, v. 30, n. 9, p. 1746-1755, Sep. 2019. DOI: 10.1681/ASN.2019010008. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6727262/
CHRONIC KIDNEY DISEASE PROGNOSIS CONSORTIUM; MATSUSHITA, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet, v. 375, n. 9731, p. 2073-2081, Jun. 2010. DOI: 10.1016/S0140-6736(10)60674-5. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60674-5/abstract
LEVEY, A. S.; CORESH, J. Chronic kidney disease. The Lancet, v. 379, n. 9811, p. 165-180, Jan. 2012. DOI: 10.1016/S0140-6736(11)60178-5. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60178-5/abstract
IX, J. H.; SHLIPAK, M. G. The promise of biomarkers in evaluating CKD. Kidney International Reports, v. 7, n. 1, p. 10-12, Jan. 2022. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8720581/
EMPA-KIDNEY COLLABORATIVE GROUP. Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, v. 388, n. 2, p. 117-127, Jan. 2023. DOI: 10.1056/NEJMoa2204233. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2204233